Clinical Trials
12 trialsNCT04150497 2025-09-09
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Phase 1/2 Recruiting
NCT05607420 2025-08-24
NatHaLi-01
Cellectis S.A.
Phase 1/2 Recruiting
NCT00199030 2023-03-20
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
Goethe University
Phase 2 Completed
NCT05557903 2022-09-28
Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Lanzhou Institute of Biological Products Co., Ltd
Phase 1 Unknown
NCT00040846 2020-01-29
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00129753 2018-11-08
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00118352 2017-05-30
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00683046 2016-11-22
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Phase 2 Completed
NCT00923182 2015-04-30
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sanofi
Phase 1 Completed
NCT00328198 2014-03-13
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Phase 2 Completed
NCT00027560 2013-01-07
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00071396 2012-08-07
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
M.D. Anderson Cancer Center
Phase 2 Completed